Cost-effectiveness model of recombinant FVIII versus emicizumab treatment of patients with severe hemophilia A without inhibitors

Authors:

Sun S, Wu Y, McDermott M and van Keep M

Publication type:

Conference Proceedings – Poster

Publication Name:

61st American Society of Hematology Annual Meeting

Citation:

Sun S, Wu Y, McDermott M and van Keep M. Cost-effectiveness model of recombinant FVIII versus emicizumab treatment of patients with severe hemophilia A without inhibitors. 61st American Society of Hematology Annual Meeting. Orlando, FL, USA. 7–10 December 2019. Poster 2102.

⟵ Back to Search Results

By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies